Compare INMB & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INMB | ICMB |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 38.8M |
| IPO Year | 2019 | N/A |
| Metric | INMB | ICMB |
|---|---|---|
| Price | $1.64 | $2.77 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | ★ 373.2K | 23.4K |
| Earning Date | 10-30-2025 | 11-12-2025 |
| Dividend Yield | N/A | ★ 18.74% |
| EPS Growth | N/A | ★ 31.51 |
| EPS | N/A | ★ 0.38 |
| Revenue | $50,000.00 | ★ $17,931,778.00 |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | N/A | $4.75 |
| P/E Ratio | ★ N/A | $7.24 |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $2.46 |
| 52 Week High | $11.64 | $3.47 |
| Indicator | INMB | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 50.71 |
| Support Level | $1.58 | $2.75 |
| Resistance Level | $1.72 | $2.89 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 63.64 | 47.50 |
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.